{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:53:08Z","timestamp":1792641188506,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,27]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Eliglustat treatment resulted in stable mean hemoglobin concentration, platelet count, and spleen and liver volumes for up to 4 years. Mean bone mineral density z scores also remained stable and were maintained in the healthy reference range for up to 4 years.<\/jats:p>","DOI":"10.1182\/blood-2016-12-758409","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T02:10:50Z","timestamp":1486433450000},"page":"2375-2383","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":80,"title":["Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy"],"prefix":"10.1182","volume":"129","author":[{"given":"Timothy M.","family":"Cox","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Drelichman","sequence":"additional","affiliation":[{"name":"Hospital de Ni\u00f1os Ricardo Guti\u00e9rrez, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Cravo","sequence":"additional","affiliation":[{"name":"State Institute of Haematology \u201cArthur de Siqueira Cavalcanti,\u201d Rio de Janeiro, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Balwani","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Andrew","family":"Burrow","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lukina","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology, Moscow, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Rosenbloom","sequence":"additional","affiliation":[{"name":"Cedars-Sinai\/Tower Hematology Oncology, Beverly Hills, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[{"name":"Lysosomal Disorders Unit, O&O Alpan, LLC, Fairfax, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Watman","sequence":"additional","affiliation":[{"name":"Hospital Ramos Mejia, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"El-Beshlawy","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Cairo University, Cairo, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia","family":"Pedroso","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Universidade Federal do Paran\u00e1, Curitiba, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J. M.","family":"Gaemers","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme, Cambridge, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Tayag","sequence":"additional","affiliation":[{"name":"Prometrika LLC, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Judith","family":"Peterschmitt","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme, Cambridge, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111906034873400_B1","doi-asserted-by":"crossref","article-title":"Gaucher disease","author":"Grabowski","DOI":"10.1007\/978-1-4615-3010-7_5"},{"issue":"9645","key":"2019111906034873400_B2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"2019111906034873400_B3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111906034873400_B4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2019111906034873400_B5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","article-title":"Revised recommendations for the management of Gaucher disease in children","volume":"172","author":"Kaplan","year":"2013","journal-title":"Eur J Pediatr"},{"issue":"5","key":"2019111906034873400_B6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"2019111906034873400_B7","article-title":"A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration","author":"Peterschmitt","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"2019111906034873400_B8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"2019111906034873400_B9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111906034873400_B10","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.ymgme.2014.12.179","article-title":"ENGAGE: a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: results after 18 months","volume":"114","author":"Mistry","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2019111906034873400_B11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol Dis"},{"issue":"20","key":"2019111906034873400_B12","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111906034873400_B13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat","volume":"43","author":"Kamath","year":"2014","journal-title":"Skeletal Radiol"},{"issue":"9985","key":"2019111906034873400_B14","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2019111906034873400_B15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2008.12.015","article-title":"A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1","volume":"96","author":"Kishnani","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"12","key":"2019111906034873400_B16","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am J Hematol"},{"issue":"4 Suppl 5","key":"2019111906034873400_B17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"issue":"1","key":"2019111906034873400_B18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1750-1172-7-102","article-title":"Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study","volume":"7","author":"Cox","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2019111906034873400_B19","author":"Zavesca (miglustat)"},{"issue":"9214","key":"2019111906034873400_B20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"2019111906034873400_B21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.2000.02177.x","article-title":"Withdrawal of enzyme replacement therapy in Gaucher\u2019s disease","volume":"110","author":"Elstein","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111906034873400_B22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2010.05.001","article-title":"Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply","volume":"46","author":"Zimran","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"2019111906034873400_B23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13023-015-0275-0","article-title":"Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1","volume":"10","author":"Stirnemann","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2019111906034873400_B24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"2019111906034873400_B25","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","article-title":"Gaucher disease and cancer incidence: a study from the Gaucher Registry","volume":"105","author":"Rosenbloom","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111906034873400_B26","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.ymgme.2014.12.272","article-title":"CYP2D6 phenotype-based dosing of eliglustat","volume":"114","author":"Turpault","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2019111906034873400_B27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2019111906034873400_B28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","article-title":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","volume":"117","author":"Balwani","year":"2016","journal-title":"Mol Genet Metab"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/17\/2375\/1400197\/blood758409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/17\/2375\/1400197\/blood758409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T11:07:23Z","timestamp":1574161643000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/17\/2375\/35964\/Eliglustat-maintains-longterm-clinical-stability"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,4,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-12-758409","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]}}}